MeiraGTx Holdings plc (MGTX)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, MeiraGTx Holdings plc keeps $50 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 12
in 63 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
About MeiraGTx Holdings plc
MeiraGTx Holdings plc is a NASDAQ-listed biotechnology company developing genetic medicines for inherited retinal disease, xerostomia, and neurologic disorders. In FY2025, it generated $81.4 million in revenue. Founded in 2015, MeiraGTx operates from New York City and has built its business around a pipeline of clinical-stage programs and platform technology.
Today's Snapshot
MGTX opened 1.8% below yesterday's close, while its sector was flat.
Trading Volume
Below 10d avg (679.3K)
151K
vs S&P 500 Today
Underperforming Market
-1.24%
Updated: September 10, 2026 at 14:48 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$10.45 - $13.69Buy
- RSI (14)43.78Neutral
- Stochastic %K (14, 3, 3)11.52Buy
- MACD Level (12, 26)0.14Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.